UB-221

BIOLOGICAL4 trials

Sponsors

United BioPharma, UBP Greater China (Shanghai) Co., Ltd

Conditions

Chronic Idiopathic UrticariaChronic Spontaneous UrticariaUrticaria Chronic

Phase 1

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients

CompletedNCT03632291

United BioPharmaUrticaria Chronic

Start: 2019-04-09End: 2021-01-19Updated: 2022-05-13

Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria

Not yet recruitingNCT04175704

United BioPharmaChronic Idiopathic Urticaria

Start: 2023-12-30End: 2026-01-30Target: 32Updated: 2022-10-03

Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of UB-221 in Healthy Volunteers

UBP Greater China (Shanghai) Co., LtdChronic Spontaneous Urticaria

Start: 2023-12-01End: 2025-06-30Target: 15Updated: 2022-05-18

Phase 2

A Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous Urticaria

United BioPharmaChronic Spontaneous Urticaria

Start: 2022-10-05End: 2023-12-31Target: 25Updated: 2022-10-07